Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

3.38
-0.5100-13.11%
Pre-market: 3.32-0.0600-1.78%05:00 EDT
Volume:4.35M
Turnover:15.91M
Market Cap:281.92M
PE:-2.41
High:4.12
Open:3.48
Low:3.13
Close:3.89
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:49.56M
Volume Ratio:3.78
T/O Rate:8.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:24.64
PE(LYR):-2.64

Loading ...

Analyst Maintains Buy Rating on PYXS and Reiterates $6 Price Target on Promising MICVO Data

TIPRANKS
·
15 hours ago

Pyxis Oncology is Maintained at Overweight by Wells Fargo

Dow Jones
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)

TIPRANKS
·
Yesterday

Pyxis Oncology price target raised to $19 from $12 at Wells Fargo

TIPRANKS
·
Yesterday

Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Pyxis Oncology Reports Promising MICVO Phase 1 Results

TIPRANKS
·
Yesterday

Pyxis Oncology Releases MICVO Clinical Update Presentation

Reuters
·
Yesterday

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (Micvo) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M Hnscc)

THOMSON REUTERS
·
Yesterday

Pyxis Oncology - Median Progression-Free Survival 6.2 Months, 12-Month Overall Survival Probability 79%

THOMSON REUTERS
·
Yesterday

Pyxis Oncology - Micvo Demonstrates 36% Confirmed Objective Response Rate and 94% Disease Control Rate in Phase 1

THOMSON REUTERS
·
Yesterday

Pyxis Oncology - no New Safety Signals Observed; Dose Capping Reduced Adverse Events in High Body Weight Patients

THOMSON REUTERS
·
Yesterday

Pyxis Oncology to Webcast Updated Phase 1 MICVO Monotherapy Data in Recurrent/metastatic Head and Neck Cancer

Reuters
·
Yesterday

Press Release: Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Dow Jones
·
Sep 08

Pyxis Oncology Interim CEO Tom Civik Joins Fireside Chat at Wells Fargo Annual Healthcare Conference

Reuters
·
Sep 01

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Pyxis Oncology files to sell 39.2M shares of common stock for holders

TIPRANKS
·
Aug 21

Pyxis Oncology Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 18

Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained

TIPRANKS
·
Aug 18

Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target Maintained

TIPRANKS
·
Aug 15

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14